Home About us Editorial board Ahead of print Browse Articles Search Submit article Instructions Subscribe Contacts Login 
  • Users Online: 240
  • Home
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2017  |  Volume : 22  |  Issue : 1  |  Page : 109

Effect of cytochrome P450 2C19*17 allelic variant on cardiovascular and cerebrovascular outcomes in clopidogrel-treated patients: A systematic review and meta-analysis


1 Department of Gastroenterology, The Affiliated People's Hospital of Guizhou Medical University, Guizhou Province, PR China
2 Department of Internal Medicine, Guizhou Provincial Traffic Hospital, Guizhou Province, PR China

Correspondence Address:
De-Jun Cui
Department of Gastroenterology, The Affiliated People's Hospital of Guizhou Medical University, No. 83, East Zhongshan Road, Guiyang 550002, Guizhou Province
PR China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jrms.JRMS_590_16

Rights and Permissions

Background: We aimed to evaluate the associations of gain-of-function allele of CYP2C19* 17 and risk of clinical events in clopidogrel-treated patients with cardiovascular and cerebrovascular diseases (CCVDs). Materials and Methods: Literature search was conducted in PubMed, EMBASE, and Cochrane Library. Odds ratio (OR) combined with 95% confidence interval (CI) was the pooled statistics. Subgroup analysis was performed by disease type, bleeding events, and race. Results: Thirteen eligible studies involving 14,239 patients with CYP2C19* 17 carriers or noncarriers were included in the meta-analysis. CYP2C19* 17 was significantly related to decreased risk of major adverse cardiovascular and cerebrovascular events (MACCEs) in patients with coronary artery disease (CAD) (OR = 0.76, 95% CI: 0.60–0.98, P = 0.03), however, irrelevant with stent thrombosis in neither CAD nor ischemic heart disease patients. CYP2C19* 17 was also significantly linked to decreased risk of high platelet reactivity (HPR) in CCVD patients (OR = 0.61, 95% CI: 0.43–0.88, P = 0.008). Meanwhile, CYP2C19* 17 was significantly associated with bleeding risk in CCVD patients (OR = 1.89, 95% CI: 1.09–3.25, P = 0.02) but not related to major bleeding risk (OR = 1.35, 95% CI: 0.87–2.08, P = 0.18). Several outcomes in Caucasian subgroup were reverse to the overall results, such as bleeding events and HPR, which lacked significance. Conclusion: CYP2C19* 17 had a significant effect on the reduced risks of MACCE and HPR as well as increased bleeding risk, but not on the risks of stent thrombosis and major bleeding in clopidogrel-treated CCVD patients. Outcomes might be different in different races.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed150    
    Printed5    
    Emailed0    
    PDF Downloaded45    
    Comments [Add]    

Recommend this journal